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Background. Everything known about the roles, relationships, and repercussions of comorbidity in cardiovascular disease is shaped
by how comorbidity is currentlymeasured.Objectives. To critically examine how comorbidity ismeasured in randomized controlled
trials or clinical trials and prospective observational studies in acute myocardial infarction (AMI), heart failure (HF), or stroke.
Design. Systematic review of studies of hospitalized adults from MEDLINE CINAHL, PsychINFO, and ISI Web of Science Social
Science databases. At least two reviewers screened and extracted all data. Results. From 1432 reviewed abstracts, 26 studies were
included (AMI 𝑛 = 8, HF 𝑛 = 11, stroke 𝑛 = 7). Five studies used an instrument to measure comorbidity while the remaining
used the presence or absence of an unsubstantiated list of individual diseases. Comorbidity data were obtained from 1–4 different
sources with 35% of studies not reporting the source. A year-by-year analysis showed no changes inmeasurement.Conclusions.The
measurement of comorbidity remains limited to a list of conditions without stated rationale or standards increasing the likelihood
that the true impact is underestimated.
1. Introduction
Heart disease and stroke, common cardiovascular diseases,
are the third and fourth leading causes of disease burden and
the primary causes of death worldwide [1, 2]. Cardiovascular
disease (CVD), a systemic disease, rarely occurs alone so
it is common to find multiple comorbid conditions in the
setting ofCVD, particularly in the older adult populationwho
bear a disproportionate share of the comorbidity burden [3].
Comorbidity, at this time, is generally understood to be the
presence of other disease entities in the setting of an index
disease or condition [4]. However, everything known about
the roles, relationships, and repercussions of comorbidity in
CVD is shaped by how comorbidity is currently measured.
The actual burden of comorbid conditions and the impact
on outcomes in CVD may not be fully realized as a result of
methodologic limitations in prospective studies completed to
date.
A brief overview of the history of comorbidity measure-
ment will set the stage for understanding these methodologic
limitations (Table 1). During the 1970s Kaplan and Fein-
stein [5] investigated taxonomic problems with classifying
comorbidity which they defined as “any distinct additional
clinical entity that has existed or that may occur during the
clinical course of a patient who has the index disease under
study” [6, page 456-7]. According to their conceptualization,
comorbidity played one of three roles in relation to the
index disease-diagnostic, prognostic, or pathogenic [6]. From
this definition and conceptualization they then developed
criteria for classifying individuals which could be used by
other researchers [5]. Following this early work, Charlson
and colleagues [7] in the 1980s developed an instrument,
the Charlson Comorbidity Index (CCI), rather than a list
of criteria to measure comorbidity. The stated goal of the
instrument was to control for sicker individuals in longitu-
dinal clinical trials. The CCI had an advantage of simplicity
and ease of use over previous methods, such as Kaplan and
Feinstein’s [7]. In the 1990s Deyo et al. [8] and D’Hoore
et al. [9] each adapted the CCI for use with administrative
datasets. During this same timeframe Elixhauser et al. [10]
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Table 1: Historical overview of the measurement of comorbidity.
Kaplan and
Feinstein [5] Charlson et al. [7] Deyo et al. [8] D’Hoore et al. [9] Elixhauser et al. [10]
Time frame 1970s 1980s 1990s 1990s 1990s
Purpose
Classify patients
for therapeutic and
statistical reasons
Prospectively
identify persons at
greater risk of death
from comorbid
diseases
Adapted the CCI for
use with
administrative
datasets
Adapted the CCI for
use with
administrative
datasets
Predict resource use
or clinical outcomes
Original population Diabetics
Medical patients
Female breast cancer
patients
Medicare lumbar
spinal surgery
patients
Hospitalized
patients in Quebec,
CAN
Acute care patients
in CA
Measurement method
Clinician derived
from symptom
patterns, disease
duration, physical
exam, and lab tests
Clinician scored
from list of weighted
diseases
Validated against
Kaplan and
Feinstein [5]
Used ICD-9-CM
codes equivalent to
diseases in the CCI
Implemented an
algorithm to map
the ICD-9 codes to
CCI components
Developed a set of
30 comorbidities
with their
ICD-9-CM codes
Predictors of
comorbidity
Clinical (e.g.,
vascular or
nonvascular
diseases) variables
Sociodemographic
and clinical variables
Sociodemographic
variables and clinical
variables
Sociodemographic
and clinical variables
Sociodemographic
and clinical variables
Outcomes assessed
Mortality or
vascular
complications for
those patients who
survived
Mortality
Mortality, hospital
complications and
treatments,
discharge
destinations
Inpatient mortality Mortality and fiscal
Surrogate terms for
comorbidity
Episodic events,
disease, ailment,
and chronic
condition
Common conditions Chronic conditions Complications (ifiatrogenic)
Clinical condition,
preexisting
condition
CCI: Charlson Comorbidity Index, ICD: International Statistical Classification of Diseases.
developed a novel measure which defined comorbidity as a
“clinical condition that exists before a patient’s admission to
the hospital, is not related to the principal reason for the hos-
pitalization, and is likely to be a significant factor influencing
mortality and resource use in the hospital” (page 10). With
this definition Elixhauser clearly delineated that it was the
context, hospitalization, not the existence of an index disease,
which determined the definition of comorbidity. In all three
measures (Deyo, D’Hoore, and Elixhauser) comorbidity was
still viewed primarily as a burdensome clinical phenomenon.
The challenge of managing and measuring comorbidity
is gaining increased attention with the worldwide aging of
the population [11–14]. In a previous paper published by our
group of scientists [15] a systematic review and evolutionary
analysis of the use of comorbidity in the empiric literature
for adults undergoing care transitions was conducted. The
aim of that study was to answer the question as to what
was known about the definition, use, and measurement of
comorbidity in this at-risk population. However, the lack
of robust measurement in almost two thirds of the studies
limited what could be stated with any confidence about
comorbidity. Attention was drawn to the need for clarity,
transparency, and standardization in the measurement of
comorbidity in that review. Subsequently, a subgroup was
formed to target the measurement of comorbidity in our
particular area of expertise—CVD. Specifically, we returned
to the original large, comprehensive dataset of studies (𝑛 =
5, 917) and selected out those studies that identified acute
myocardial infarction (AMI), heart failure (HF), or stroke as
the index disease of the study (𝑛 = 1432). We then carefully
analyzed the measurement of comorbidity in those studies.
Our findings are presented in this paper.
Despite more than 30 years of comorbidity measurement,
a rigorous systematic review of themeasurement of comorbid
conditions in CVD outcomes research, particularly in the
AMI, HF, or stroke population, has not been conducted
and disseminated. Both clinicians and policymakers need
to know precisely what is meant by the term comorbidity
and how the comorbidity data is measured for two critical
reasons—(1) the importance of comorbidity as a descriptor
of patient populations; (2) the importance of comorbidity
as a potential predictor or modifier of the effect of clini-
cal interventions on outcomes. Imprecise measurement of
comorbidities may be creating an incomplete picture of
the problem and a misestimation of individual and health
system outcomes resulting from unmeasured or mismea-
sured comorbid conditions in CVD. In addition, variation
of comorbidity measurement across studies limits the ability
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of investigators to aggregate data and conduct meta-analyses
necessary for the development of comparative effectiveness
research and evidence-based practice protocols.
Thus, the purpose of this systematic review was to
examine the state of the measurement of comorbidity in
randomized controlled trials (RCTs) or clinical trials and
prospective observational studies of adults hospitalized for
an AMI, HF, or stroke. Specifically, we sought to answer four
key questions related to the measurement of comorbidity in
outcomes research for these three populations: (1) how is
comorbidity defined, identified, and measured in studies of
acute MI, HF, and stroke? (2) What are the psychometric
properties of the measures and indices used? (3) How were
the measures used and for what outcomes? (4) Do the
definitions, measures, or uses vary by year of publication?
2. Methods
2.1. Eligibility Criteria. Comorbidity was defined inclusively
as any other chronic condition in the presence of AMI, HF,
or stroke. To determine the earliest year of publication for
inclusion, formal measures of comorbidity were reviewed
to identify the year in which commonly used instruments
were published (earliest dated to 1969); consequently, articles
published in English between 1965 and July 31, 2009, in peer-
reviewed journals affiliated with the electronic databases
listed below were considered eligible for this systematic
review. The search was restricted to randomized controlled
trials (RCTs) or clinical trials and prospective observational
studies. The rationale for restricting to these types of trials
was to exclude studies in which the investigators did not
have control over study design related to the measurement of
comorbidity aswould take place, for example, in retrospective
analyses or registry data where existing data is used. If the
investigator had control over the measurement of comorbid-
ity (even if the data was obtained from medical records), the
study was considered eligible.
2.2. Information Sources. A comprehensive search of the lit-
eraturewas devised and conducted usingMEDLINE accessed
via PubMed, Cumulative Index of Nursing and Allied Health
Literature (CINAHL), PsychINFO, and ISI Web of Science
Social Science databases for the original dataset from our
previous study [15]. Diverse databases were used to obtain
perspectives from multiple disciplines and include both
physical and mental health comorbidities.
2.3. Search. Search terms for the original dataset [4, 13, 16]
were identified from national reports on comorbidity and
concept analyses. Search terms and strategies were developed
in consultation with a medical librarian. Although our
search strategies were specific to each database due to the
options available to customize, our basic search strategy
used the National Library of Medicine’s Medical Subject
Headings (MeSH) key word nomenclature developed for
MEDLINE. The exact search strings used in our strategy are
given in Appendix/Supplement A (See Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2013/563246).
The literature search syntax used keywords with the most
inclusive suffix. All related terms and combinations of these
terms related to the concept of comorbidity (i.e., multimor-
bidity, co-occurring, coexisting, risk factors, complications,
etc.) were used. The literature search for this current analysis
was further refined to identify studies including the diagnoses
of interest AMI, HF, and stroke as index conditions.
2.4. Study Selection
2.4.1. By Diagnosis. Selected studies were limited to those
with adult populations (age ≥ 19 years) hospitalized for an
AMI, HF, or stroke. AMI was defined as either ST ele-
vation or non-ST elevation acute MI. Heart failure was
defined as an individual having the stated diagnosis on
hospital admission (either preserved or reduced systolic
function). Stroke was defined as a focal neurologic deficit
lasting >24 hours attributed to a cerebral vascular cause of
either ischemic stroke or intracerebral hemorrhage or, of
shorter duration, a transient ischemic attack. To provide a
more homogeneous population for analysis, patients with
subarachnoid hemorrhage (often developed secondarily to
injury), unstable angina, or symptoms consistent with an
acute coronary syndrome (often a preliminary diagnosis)
without documented evidence of myocardial ischemia or
injury were excluded. Studies reporting populations with
mixed CVD diagnoses at enrollment were also excluded.
2.4.2. By Design. We included randomized controlled trials
(RCTs) or clinical trials and prospective observational stud-
ies. To be included studies had to report original data with
the baseline assessment occurring during the hospitalization
and at least one clinical site of multisite studies was to be in
the United States.This criterion, once again, provided a more
homogenous sample which would facilitate translation of the
findings into specific, contextually appropriate recommenda-
tions. Retrospective studies designed to use administrative,
registry, or public or private claims data were excluded for
the reason stated earlier. Secondary analysis, in which the
research aim was developed after the dataset existed, was
also excluded for the same reason. Meta-analyses, systematic
reviews, case reports, editorials, letters to the editor, and pilot
studies were also excluded.
2.4.3. Selection Process. Using prespecified criteria (Appen-
dix/Supplement B), each title and abstract were examined
independently by two reviewers for potential relevance. Arti-
cles included by any reviewer underwent full-text screening
where two independent reviewers read each article to deter-
mine if it met eligibility criteria. When the paired reviewers
arrived at different decisions about whether to include or
exclude an article, they reconciled the difference together
with a third-party arbitrator. Articles meeting eligibility
criteria advanced to data abstraction.
We hypothesized that RCTs, in particular, might be less
likely to use terms related to comorbidity in the primary
outcomes paper (and thus, not be identified by our search).
To account for the known prevalence of secondary analysis
in CVD trials and to improve the external validity of this
systematic review, in a second step we examined the full
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text article of each RCT identified by an excluded secondary
analysis (𝑛 = 18) from our original search which otherwise
met our inclusion criteria.The primary outcomes article and,
when published separately, the baseline characteristics or
study design articles were identified. These articles advanced
to data abstraction as a subanalysis.
2.5. Data Collection Process. The data extraction form was
piloted by three investigators with eight studies. Included
studies were then abstracted onto the data form by one
reviewer and the data confirmed by a second team member.
We employed internal quality-monitoring checks through
every phase of the project to reduce bias, enhance consistency,
and verify accuracy. Examples of internal monitoring pro-
cedures were confirmation of study eligibility at each phase
(abstract screening, full-text screening, and data abstraction),
involvement of two individuals for each level of screening
and for data abstraction of each article, and agreement of at
least two investigators on all included studies and the data
extracted.
2.6. Data Items. Abstracted data elements included first
and last author discipline, geographic study location, study
design, setting, sample size, patient characteristics (index
condition and age), definition of comorbidity, the data source
for the comorbidity data, comorbiditymeasure used, whether
the measure was modified from its original use and if so
how, stated validity and reliability of the measure, how the
comorbidity data ormeasurewas employed in the study,main
study outcomes, stated or reviewer-observed limitations of
the study related to measurement of comorbidities, and
an overview of the study (purpose or question, analytic
approach, and main study findings). Conflicting data were
resolved by a third reviewer.
2.7. Synthesis of Results. Datawere summarized across studies
to answer key questions 1–3, and then between study vari-
ations by index condition, study design and year published
were analyzed to answer key question 4. The subanalysis of
RCTs identified by excluded secondary analyses focused on
key questions 1 and 2 to determine how comorbidities were
defined, identified, and measured in this body of literature
and the psychometric properties of any indices.
3. Results
3.1. Study Selection and Characteristics. Of the 1432 CVD
publications reviewed, 26 studies (AMI 𝑛 = 8, HF 𝑛 = 11,
stroke 𝑛 = 7) and 5 RCTs (identified by excluded secondary
analyses from our original search) met the inclusion criteria
(Figure 1) and were analyzed (Table 2). The 26 studies were
primarily published in cardiology journals (𝑛 = 11), by
physicians (𝑛 = 24), and conducted in the USA (𝑛 = 25).
3.2. Synthesis of Results
3.2.1. Key Question 1: How Is Comorbidity Defined, Identified,
and Measured in Studies of Acute MI, HF, and Stroke? The
following terms were used synonymously to define comorbid
conditions: comorbid, concomitant, or underlying diseases
or conditions (𝑛 = 8), risk factors (𝑛 = 5), relevant clinical
variables or data (𝑛 = 5), patient or clinical characteristics
(𝑛 = 4), past medical history (𝑛 = 2), or chronic medical
conditions or diseases (𝑛 = 2) in the reviewed studies.
The comorbidity data were identified and obtained from 1–4
different sources for a single study including medical records
(𝑛 = 13), clinician judgment (𝑛 = 8), self/proxy report
(𝑛 = 7), or DSM-III criteria (𝑛 = 3). In 35% of the studies
(𝑛 = 9) the data source for comorbidities was not reported
(Table 3).
Comorbidities were most commonly recorded, mea-
sured, and then analyzed as the presence of individual
diseases, conditions, or risk factors (𝑛 = 21) or laboratory
values indicating disease (i.e., lipid levels) without prespec-
ified criteria given for what was or was not counted as
comorbidity. The list of individual diseases was unique to
each of the 26 studies reviewed. Diabetes was the most
frequently measured comorbidity (𝑛 = 21), followed by
hypertension (𝑛 = 19), dyslipidemia (𝑛 = 9), and COPD (𝑛 =
6). Studies generally controlled for cardiovascular diseases
other than the index condition. For example, if AMI was
the index condition, HF and stroke would be considered
comorbidity and controlled for in the analyses.The empirical
literature supporting the selection of the conditions and
diseases was not cited, and individual conditions defined by
some studies as “past medical history” were referred to as
“baseline demographics” or “characteristics” in other studies.
Definitions of comorbidity or any of the surrogate terms were
not provided in any of the reviewed studies.
The subanalysis of the RCTs identified by excluded
secondary analyses (𝑛 = 18) from our original search
revealed that three of these studies used data from primary
studies already reviewed in this paper. The 15 remaining
secondary analysis papers used data from five clinical trials.
Each of these clinical trials used a list of conditions. All five
trials (CADILLAC [43], ENRICHD [44], ExTRACT-TIMI
25 [45], GUSTO [46], and VALIANT [47]) identified and
analyzed comorbidity as the presence or absence of reported
conditions which were identified by laboratory values or
preadmission pharmacological therapy. When compared by
index diagnosis (e.g., AMI, HF, stroke), the measurement of
comorbidities reported in each trial revealed the use of a list
of conditions unique to each trial.
3.2.2. Key Question 2:What Are the Psychometric Properties of
the Measures and Indices Used? Only five of the 26 studies
and one trial in our subanalysis sample reported the use
of an established instrument to measure comorbidities [17,
18, 25, 26, 36, 44]. In these five studies and one trial, no
evidence was included for the construct validity or reliability
(via coefficient alpha) of the instrument for use with the
specific study population. All but one study [17] in the overall
review (𝑛 = 25) had sufficient sample size to provide for the
assessment of these statistics to allow for greater confidence
in the interpretation of the results from the instruments.
3.2.3. Key Question 3: How Were the Measures Used and
for What Outcomes? Three studies examined only medical
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Search from 1965-July 31, 2009
Papers identified by database:
Inclusion criteria:
Empirical studies
Published in English 
Peer-reviewed journals
US healthcare setting
1432 papers selected and  
screened by title and  
abstract for inclusion  
not AMI, HF, or stroke AND 
clinical trial
not original data 
identified by an excluded 
secondary analys is papers
from our original search
Final set of papers 
included in analysis 
Full text papers screened for 
5, 917 papers after  
duplicates removed
Medline (n = 4, 660)
CINAHL (n = 82)
PsychINFO (n = 645)
ISI Web of science (n = 1, 489)
Humans ≥19 years of age
inclusion (n = 151)
(n = 26)
Subanalysis of RCTs (n = 5)
Excluded papers (n = 117)
Excluded abstracts (n = 1280)
Excluded papers (n = 4, 485)
Figure 1: PRISMA flowchart.
comorbidities using the CCI. Chin and Goldman [25] used
the CCI as a summarymeasure of coexisting diseases to iden-
tify predictors of readmission or death for patients admitted
to the hospital with shortness of breath, fatigue, or HF. Rocha
and colleagues [17], with Charlson as a coauthor, used the
CCI to assess medical comorbidity in a study that evaluated
potential predictors of posttraumatic stress disorder in AMI.
The ENRICHD trial [44] tested an intervention for treating
depression and low perceived social support after AMI. The
mean CCI score was reported as a medical characteristic
in the primary outcomes paper of the ENRICHD trial but
not the baseline characteristics paper or secondary analysis
that was identified in our search. The primary outcomes
paper explained the CCI’s use only as a footnote in the
demographics table.
Two studies examined comorbid depression using differ-
ent instruments, while a third study examined depression
plus other medical conditions. Kishi and colleagues [36]
assessed comorbid depression in stroke patients using the
Hamilton Depression Rating Scale. Romanelli et al. [18]
measured comorbid depression in older adults with AMI
using the Beck Depression Inventory. Fulop et al. [26]
examined both comorbid depression and medical conditions
separately using the Duke Severity of Illness Checklist to
derive both an overall disease severity score and then an
individual comorbidity score to control the effects of severity
of illness on medical resource use in older adults with HF
while also examining comorbid depression as measured by
the Geriatric Depression Scale.
Comorbidity was used in multiple ways in the analyses
of the reviewed studies (Table 3). The majority of the studies
(𝑛 = 20) used comorbidity as a covariate. However, comor-
bidity was also used as a predictor (𝑛 = 7), outcome (𝑛 = 3),
and descriptor (𝑛 = 2). Reported outcomes of comorbidity
were increased morbidity (𝑛 = 12), health service utilization
(𝑛 = 7), mortality (𝑛 = 7), and quality of life (𝑛 = 3).
3.2.4. Key Question 4: Do the Definitions, Measures, or Uses
Vary by Year of Publication? A year-by-year analysis of the
studies showed no changes in definitions or measurement
over the 14 years of publication. No pattern of improving
definition and operationalization of the variable, such as stan-
dardization or a theoretically derived definition, or greater
use of validated instruments was foundwhen the studies were
analyzed by year or decade or when they were examined by
study design.
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Table 2: Demographics of the studies by diagnosis.
AMI HF Stroke
Number of studies 8 [17–24] 11 [25–35] 7 [36–42]
Publication years 1997 [22]–2008 [17, 20] 1997 [25]–2009 [35] 1995 [38]–2009 [42]
Journal type
Cardiac [20, 22, 24],
nephrology [19], general
medicine [21], nursing
[23], psychology [17],
and geriatric [18]
Cardiac
[25, 29–32, 34, 35],
psychology [26, 33],
general medicine [27],
and geriatric [28].
Neurology/stroke
[36, 39–42], cardiology
[37], and psychology
[38]
Author discipline
Medicine [18, 19, 21, 24],
medicine plus another
discipline [17, 20, 22], or
nursing [23]
Medicine
[25–27, 29–32, 34, 35],
medicine plus another
discipline [33], or
nursing [28]
Medicine [36–42]
Country of study USA except one [22] USA USA
Study question related to comorbidity 3 [17, 19, 21] 4 [25, 26, 31, 33] 3 [36, 38, 40]
Used a comorbidity instrument CCI [17]
CCI [25], Duke Severity
of Illness Checklist [26],
Geriatric Depression
Scale [26], and Beck
Depression Inventory
[31, 33]
Hamilton Depression
Rating Scale [36]
Main outcomes
Mortality [18, 19, 21, 22],
morbidity
[20, 21, 23, 24], and
disability [17]
Mortality [25, 27, 31],
disability [26, 28, 33],
QoL [28], and health
service utilization
[25, 28–30, 32, 34]
Morbidity [38–40, 42],
QoL [37, 38], and health
service utilization [41]
CCI: Charlson Comorbidity Index, QoL: quality of life.
4. Discussion
4.1. Summary of Evidence. The purpose of this systematic
review was to examine the measurement of comorbidity
in CVD clinical trials. We identified that 21 out of 26
studies measured comorbidities with a list of unsubstantiated
diseases without defining comorbidity while using multiple
data sources or leaving the data source unknown. This is
particularly troubling given the multiple valid and reliable
measures available to researchers [11, 48]. In the small
number of studies utilizing an instrument, the CCI was
the most frequently used. Equally troubling was the finding
that measurement did not change or advance during a time
period when the methodology of CVD trials was improving
overall [49]. In the following section, we will discuss the
two challenges experienced in conducting this systematic
review followed by the three potential threats to the validity
of comorbidity measurement that we identified.
4.2. Two Challenges in Conducting a Review of Comorbidity
Measurement in CVD Trials. A major challenge in con-
ducting this review arose from the a priori decision to use
only prospectively collected data. While this decision was
made to capture studies where the investigators designed
the study and therefore determined how comorbidity was
measured, this resulted in a surprisingly low number of
studies. Thus, while we started with a relatively robust pool
(𝑛 = 1432), resulting in 151 studies for full screening,
when all mixed cohort populations, registry studies, and
secondary analysis or retrospective studies were excluded
the final set of studies was a relatively small sample of 26.
We addressed this challenge by then adding a subanalysis of
the methods papers of the RCTs identified (but excluded)
as secondary analyses. This particular challenge highlights
thatmany publishedCVDpapers are derived frompreviously
collected data for which the measurement of comorbidity
was never the main outcome of interest. If the validity of
the comorbidity data in the parent trial suffers from internal
threats, these threats carry over into all subsequent secondary
analyses and what is known or knowable about comorbidity
suffers. This systematic review draws attention to the critical
need to strengthen themeasurement of comorbidity in future
multinational CVD clinical trials so that the relationships
between comorbidity and outcomes can be trusted. The
trustworthiness of these relationships becomes especially
important when translating intervention studies into clinical
practice for more heterogeneous populations.
A second challenge was the lack of a single, logically
coherent, definition of comorbidity in CVD research. Despite
constructing an electronic literature search using related
terms (𝑛 = 27) identified from national reports and
concept analyses on the topic of comorbidities [15], it is likely
that studies of adults hospitalized for AMI, stroke, or HF
were not identified. In addition, focusing on clinical trials,
with their known exclusion of the complex chronically ill,
may have introduced bias in the findings. The exclusion
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Table 3: Studies in final analysis.
Investigators Indexcondition Sample
Definition of
comorbidity
Surrogate terms
Diseases listed
(instrument) Data source
Comorbidity used
as
Afshinnia et al.
[19] AMI 𝑛 = 220
No definition
comorbid diseases,
conditions,
underlying diseases
HTN, DM, HF, sepsis,
anemia,
cardiorespiratory arrest
Patient, family
Clinician judgment
Medical records
Covariate
Afzal et al. [34] HF 𝑛 = 163
No definition
comorbid
conditions, risk
factors
HTN, DM, Hx of
MI/stroke
Clinician judgment
Medical records Covariate
Ariyarajah et al.
[37] Stroke 𝑛 = 66
No definition
common medical
comorbidities
risk factors
Hx of stroke, Afib
CAD, MS, MR, dilated,
restrictive, and
hypertrophic
cardiomyopathy,
hyperlipidemia, DM,
hyper/hypothyroid,
COPD, HF, MI
Medical records Covariate
Castillo et al.
[38] Stroke 𝑛 = 142
No definition
comorbid
depression
Depression
Clinical judgment
using DSM-III
criteria
Predictor
interaction term
Chin and
Goldman [25] HF 𝑛 = 257 No definition
Hx of HF, MI, HTN, DM
(Charlson Comorbidity
Index)
Medical records Predictor andcovariate
Freedland et al.
[33] HF 𝑛 = 613
No definition
comorbid medical
condition
Hx of HF, MI, anemia,
arthritis, CAD, CVA,
DM, GI disorder, HTN,
COPD, sleep apnea,
renal disease
Hx of 1 or more
comorbid medical
conditions
(Beck Depression
Inventory)
Clinical judgment
using the
diagnostic
interview schedule
medical records
Predictor,
covariate, outcome
Fulop et al. [26] HF 𝑛 = 203 No definition
(Geriatric Depression
Scale;
Duke University
severity of illness
checklist)
Patient
Clinician judgment
Medical records
Covariate
Goonewardena
et al. [32] HF 𝑛 = 75 No definition
HTN, DM, COPD, CKD,
Afib, depression Unclear Covariate
Jiang et al. [31] HF 𝑛 = 1,006
No definition
concomitant
illnesses, clinical
characteristics
Hx MI, DM Medical records Covariate
Kimmelstiel
et al. [30] HF 𝑛 = 200 No definition HTN, DM
Patient
Medical records Covariate
Kishi et al. [36] Stroke 𝑛 = 301 No definition (Hamilton DepressionRating Scale)
Patient
Clinician judgment
using the DSM-III
criteria
Predictor
Sert Kuniyoshi
et al. [20] AMI 𝑛 = 92
No definition
characteristics
HTN, DM, HF
hypercholesterolemia Unclear Covariate
Lakkireddy et al.
[21] AMI 𝑛 = 376
No definition
characteristics
HTN, Hx MI, DM
hypercholesterolemia Unclear Predictor covariate
Malki et al. [29] HF 𝑛 = 187 No definition HTN, DM, Hx MI,stroke Clinician judgment Covariate
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Table 3: Continued.
Investigators Indexcondition Sample
Definition of
comorbidity
Surrogate terms
Diseases listed
(instrument) Data source
Comorbidity used
as
Marrugat et al.
[22] AMI 𝑛 = 1460
No definition
clinical variables
CKD, COPD, DM, HTN,
PVD Unclear Covariate
Mehta et al. [39] Stroke 𝑛 = 80
No definition
clinical data, other
diseases, risk factors
HTN, DM, CHD,
dyslipidemia Unclear Covariate
Moroney et al.
[40] Stroke 𝑛 = 185
No definition
risk factor
Angina, MI, HF, and
valvular heart disease
Patient
Family
Key informants
Medical record
Covariate
Naylor et al. [28] HF 𝑛 = 239
No definition
medical conditions,
health conditions
CAD, HTN, Afib, DM,
pulmonary disease Medical record Covariate
Quinn [23] AMI 𝑛 = 100
No definition
disease history
clinical variables
past medical history
Hx of Angina, CAD,
HTN, DM,
hyperlipidemia, smoking
(past/current), previous
MI
Medical record Covariate
Rehan et al. [24] AMI 𝑛 = 92
No definition
baseline
demographics
Hx of CAD, HTN, HF,
DM Unclear Descriptor
Rocha et al. [17] AMI 𝑛 = 25 No definition
(Charlson Comorbidity
Index for medical
comorbidities;
SCID and IES-R for
PTSD)
Patient
Medical record Predictor, outcome
Romanelli et al.
[18] AMI 𝑛 = 153 No definition
Depression
DM, COPD, HTN,
hyperlipidemia, CKD,
(Beck Depression
Index)
Patient
Clinician judgment
using the DSM-III
Medical record
Predictor,
outcome
Sakr et al. [27] HF 𝑛 = 34 No definitionrisk factor
CAD, CKD, pneumonia,
DM, HTN, HF Unclear Covariate
Shah et al. [41] Stroke 𝑛 = 81 No definitionclinical data
DM, HTN,
hypercholesterolemia,
CAD, Afib, Hx of stroke
Unclear Covariate
Soman et al. [35] HF 𝑛 = 201
No definition
relevant clinical
variables
CAD, Hx of MI
DM, HTN, lipid
abnormalities
Clinician judgment Covariate
Stead et al. [42] Stroke 𝑛 = 418 No definition HTN, DM, Afib, Hx ofTIA, and stroke Unclear Descriptor
AMI: acute myocardial infarction, Afib: atrial fibrillation, CAD: coronary artery disease, CHD: chronic heart disease, CKD: chronic kidney disease, COPD:
chronic obstructive pulmonary disease, CVA: cerebral vascular accident, DM: diabetes mellitus, DSM-III: American psychiatric association diagnostic and
statistical manual of mental disorders, 3rd edition, GI: gastrointestinal, HF: heart failure, HTN: hypertension, Hx: history, IES-R: impact of event scale-revised,
MI: myocardial infarction, MS: mitral stenosis, MR: mitral regurgitation, PVD: peripheral vascular disease, SCID: structured clinical interview for DSM
disorders, TIA: transient ischemic attack.
Diseases listed are in regular font. Instruments used in the study are in bold.
of meta-analyses, because of their potential for including
studies already captured in the systematic search, may have
excluded equally valid, but unincluded, studies. Adding to
this challenge there was a lack of salient information about
comorbidity and its measurement in the studies that we did
identify and review. We hypothesize that manuscript length
restrictions in the particular studies that we reviewed could
have constrained the capacity of authors to fully describe
each variable and source of information. Our review of
the methodology papers from the subanalysis of the larger
clinical trials supported this, when little to no information
was found regarding rationales for particular conditions
measured or the data source on the conditions. Or it is
possible that among clinicians the definitions of risk factor or
clinical characteristics may be assumed common knowledge
needing no further explanation.However, this review showed
that despite the paucity of information on the measurement
of comorbidity, what could be determinedwas that each study
Nursing Research and Practice 9
uniquely operationalized the term comorbidity and how it
was employed statistically.
4.3. Three Potential Threats to the Validity of
Comorbidity Measurement
4.3.1. Heterogeneity in Data Sources. Heterogeneity in the
comorbidity data or what is measured was noted in a recent
systematic review of multimorbidity instruments which
found that 59% of the studies analyzed used a list of diseases
without any indication of the rationale behind the selection
of the specific conditions [11]. Our analysis of CVD studies
supports this finding but highlights an additional potential
threat in what is measured—the lack of definitions for what is
considered comorbidity.The selection of conditionswithout a
stated rationale, as we found, presents an internal threat to the
validity of the study by potentially introducing investigator
bias. For example, important confounding conditions could
be excluded because investigators have not traditionally
measured them. The threat is increased when data for
these comorbidity lists come from multiple sources such as
patient or proxy self-report, clinician assessment, and med-
ical records as was also found in this review. Concordance
between different data sources in comorbidity is known to
be problematic [50]; however, the use of a validated index
does not assure freedom from internal threats to validity.The
two studies in our review that used the CCI appear to have
accrued the information from chart review [25] or clinician
administered interview [17]—two very different data sources
making comparisons of their findings problematic. Further
heterogeneity in the data arises from the use of administrative
datasets as noted earlier [51]. The Elixhauser measure and
Deyo and D’Hoore’s adaptation of the CCI all depend
on International Statistical Classification of Diseases (ICD)
codes. Use of ICD codes has such problems as the known
underreporting of comorbidities [9], difficulties in distin-
guishing comorbidities from complications of treatment or
severity indicators for the index disease [10], code selection
associated with better payment [8], and database-specific
limitations (e.g., number of comorbidities allowed by the
database) [9]. But despite these limitations, each comorbidity
measure has been shown to strongly predict complications,
functional decline, and death in hospitalized adults [7–10].
In recognizing these limitations, investigators leading
prospective studies have the opportunity to design the mea-
surement of comorbidities to reduce the likelihood of hetero-
geneity with its missingness and inaccuracies. Recognizing
that 50% of the studies in this review relied on medical
records as a data source for comorbidity, it might be informa-
tive to review and synthesize how comorbidity is measured
among studies relying on medical record data accrued for
clinical practice rather than research. Whether the use of
clinical data versus research data results in differences in
prediction of patient outcomes is an interesting and needed
line of inquiry.
4.3.2. Variability in Measurement. Variability in measure-
ment practices or how comorbidity is measured presents
the second potential threat to the validity of comorbidity
measurement in CVD trials. A national report on comor-
bidities highlighted that the definition and measurement of
comorbidity in clinical trials is known to vary based on the
aims and outcomes of the studies [4]. Comorbidity is gaining
increasing attention while its measurement, as documented
in this review, apparently remains static over time and
without standards for parameters. Past and current trends in
measurement may reflect mentoring networks and research
training rather than best practice (e.g., measurement is
guided by who is part of the research team and how they
were trained). This variability presents several threats. For
example, in one HF study reviewed [25] the investigators
used the CCI to measure comorbidity while also controlling
for HTN, creatinine, and DM (all measured in the CCI)
individually in some of their analyses. This leads to poten-
tially weighting or confounding in the analysis and makes
assessing the outcomes problematic. In observational stud-
ies, the prevalence of particular comorbid conditions may
be under (or over) estimated or under (or over) reported,
and their influence on outcomes unknown if this is a rou-
tine practice. When comparing clinical trials with similar
aims and outcomes, an accurate estimate of the effect size
may be difficult to assess if comorbidities were measured
differently in different intervention studies. Meta-analyses
may be unknowingly amalgamating vastly different popula-
tions because of variability in the measurement. This paper
confirms this documented variability in measurement.
4.3.3. Meaningfulness of the Findings. The third potential
threat to the validity of comorbidity has direct patient care
implications. Even if the measurement of comorbidity was
to improve significantly, the impact of this to the individual
patient is unclear. While we may be able to report the
amount of variance that a particular disease accounts for
in a particular outcome, as to whether that is meaningful
to the individual patient is unknown and perhaps currently
unknowable. Furthermore, there may be unknown, unmea-
sured confounders that would come to light when patients’
chronic illness experiences are carefully explored. For exam-
ple, by exploring the patient experience of comorbidity we
might discover why patient nonadherence to treatment rates
in chronic illness (comorbidity) has stayed fairly stable over
several decades at approximately 50% [52]. This lack of
empiric studies into the patient comorbidity experience was
noted by our group in an earlier conceptual study [15]. By
continuing to measure comorbidity as we always have we
derive no new knowledge that might lead to improvements
in patient care.
5. Conclusion
This systematic review suggested that the burden of comor-
bidity for individuals with CVDmay not be fully realized as a
result of methodologic limitations in the prospective studies
we reviewed. CVD outcomes research would benefit from the
development of a standard definition and standard measures
that all studies could use. Furthermore, research is needed
into how to best capture and measure patient-reported
10 Nursing Research and Practice
experiences with comorbid conditions. We recommend that
future studies be designed using valid and reliable indices
or appropriate or theoretically chosen comorbidities when
indices are not appropriate and transparency in all studies by
providing the rationale and limitations for one approach to
measuring comorbidities over another.
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